Videos

Jesse Fann, MD, MPH, spoke about what he hopes to accomplish during the 2-year term of his APOS presidency.

Linda E. Carlson, PhD, RPsych, asserted mindfulness programs have strong evidence in managing psychosocial symptoms, but require increasing access for use.

In this segment, the discussion centers on proactive toxicity management strategies in EGFR mutated metastatic non-small cell lung cancer.

In this segment, Dr. Devarakonda asks Dr. Rous to interpret the clinical implications of the FDA approval of subcutaneous amivantamab in combination with lazertinib, including the availability of once monthly dosing.

Yesne Alici, MD, discussed cancer-related fatigue and cognitive impairment and addressed sleep disturbances and AEs such as anemia to improve outcomes.

It is a good option to move to BCMA-directed therapy for patients with multiple myeloma after an initial relapse, said María-Victoria Mateos, MD, PhD.

PET-negative soft tissue disease may prompt a rebiopsy, particularly in enriching for treatment-emergent neuroendocrine prostate cancers.

NEADORA data highlights why early NGS guides resectable EGFR lung cancer care, favoring perioperative osimertinib and avoiding checkpoint inhibitors.

Team Roswell presents ABC Consortium real-world data from 15 US centers comparing second-line outcomes with axi-cel, liso-cel, and a third CAR T product in large B-cell lymphoma, including manufacturing timelines, bridging therapy, response, survival, and key toxicities. The discussion highlights faster vein-to-vein time and fewer out-of-spec products with axi-cel, broadly similar efficacy between axi-cel and liso-cel, and higher rates of cytokine release syndrome/neurotoxicity with axi-cel alongside lower acute toxicity with liso-cel. Team NYC cross-examines the interpretation, especially the limited sample for the third product, and the panel pivots to practical post–CAR T survivorship issues like infections, hypogammaglobulinemia, IVIg use, and the need for more standardized supportive-care practices.

Experts explain how adjuvant osimertinib changes post-surgery EGFR lung cancer care, from rapid testing to real-world adherence.

Ryan H. Moy, MD, PhD, noted that patients with early-onset esophagogastric cancer tend to have more advanced disease.

According to Yoanna S. Pumpalova, MD, both early-onset and later-onset colorectal cancers are genetically similar in terms of somatic mutations.

Venlafaxine was found to be an effective treatment for patients with breast cancer who are experiencing vasomotor symptoms.

Two genitourinary oncologists discussed research examining germline platelet polygenic risk scores to predict survival outcomes in kidney cancer.

It is unlikely that guidelines recommend screening patients younger than 45 years for colorectal cancer, according to Yoanna S. Pumpalova, MD.

Patients with high-risk or intermediate-risk disease may benefit from allogeneic stem cell transplantation as a potentially “curative approach.”

In this segment, Dr. Devarakonda asks Dr. Singhi to address how route of administration and treatment logistics influence clinical decision making in EGFR mutated metastatic non-small cell lung cancer.

In this segment, Dr. Devarakonda asks Dr. Rotow to move beyond clinical trial data and discuss the real world factors that influence first line treatment selection in EGFR mutated metastatic non-small cell lung cancer.

The NHS-Galleri study findings showed that multicancer screening with the Galleri test did not reduce the number of cancers found at stage III or IV.

The addition of Bacillus Calmette-Guérin to ERBT significantly reduced 1-year recurrence rates among patients with high-risk, muscle-invasive disease.

Ben Brewer, PsyD, discussed the 5 core components of cognitive behavioral therapy for insomnia.

Donor availability may influence the treatment decision-making process regarding the use of transplantation for those with myelofibrosis.

Team Roswell presents ABC Consortium real-world data from 15 US centers comparing second-line outcomes with axi-cel, liso-cel, and a third CAR T product in large B-cell lymphoma, including manufacturing timelines, bridging therapy, response, survival, and key toxicities. The discussion highlights faster vein-to-vein time and fewer out-of-spec products with axi-cel, broadly similar efficacy between axi-cel and liso-cel, and higher rates of cytokine release syndrome/neurotoxicity with axi-cel alongside lower acute toxicity with liso-cel. Team NYC cross-examines the interpretation, especially the limited sample for the third product, and the panel pivots to practical post–CAR T survivorship issues like infections, hypogammaglobulinemia, IVIg use, and the need for more standardized supportive-care practices.

Julian Hong, MD, MS, stated that the demand for highly specialized teams trained to combat the onset of mental health disorders outpaces the supply.

FcRH5 is emerging as a potentially highly active target for cellular therapies in multiple myeloma care, said Natalia Neparidze, MD.

According to a study published in Cancer, new-onset mental health disorders increased the risk of all-cause mortality in patients with cancer.

Adverse effects of novel immunotherapies appear controllable compared with chemotherapy in hematologic malignancies, according to Guenther Koehne, MD.

Newer generations of BTK inhibitors may have fewer cardiac toxicities compared with earlier iterations, according to Nicole Lamanna, MD.

Julia E. McGuiness, MD, discussed the timeline for mammographic density changes following significant weight loss.

Scott Tagawa, MD, MS, FACP, FASCO, evaluated how the rPFS improvement with lutetium 177 could help integrate the treatment into the frontline metastatic HSPC setting.